Showing results (451-460 of 608) with videos related to
Sort By:
Pageof 61
Pathogens (Basel, Switzerland)|July 28, 2026
Patient-Reported Health-Related Quality of Life Impact and Symptom Severity in Patients with Lyme Borreliosis in the Burden of Lyme Disease (BOLD) StudyHolly Yu, Amanda R Mercadante, Kate Halsby, et al.Clinical Oral Investigations|May 18, 2013
The randomized shortened dental arch study: oral health-related quality of lifeS Wolfart, F Müller, J Gerß, et al.Pathogens (Basel, Switzerland)|March 28, 2026
Clinical Manifestations of Lyme Borreliosis in Europe: Burden of Lyme Disease Study (BOLD), 2021-2022Kate Halsby, Alexandra Loew-Baselli, Franc Strle, et al.Pharmacoepidemiology and Drug Safety|February 26, 2021
Suitability of databases in the Asia-Pacific for collaborative monitoring of vaccine safetyKatherine M Duszynski, James H Stark, Catherine Cohet, et al.International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|September 21, 2024
Incidence of symptomatic Lyme borreliosis in nine European countriesFrederick J Angulo, Emily Colby, Anne-Mette Lebech, et al.Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|March 7, 2022
Defining cognitive impairment in amyotrophic lateral sclerosis: an evaluation of empirical approachesCorey T McMillan, Joanne Wuu, Katya Rascovsky, et al.Journal of Dental Research|June 16, 2012
The randomized shortened dental arch study: 5-year maintenanceS Wolfart, B Marré, B Wöstmann, et al.Emerging Infectious Diseases|August 23, 2023
Validation of Claims-Based Algorithm for Lyme Disease, Massachusetts, USANoelle M Cocoros, Sheryl A Kluberg, Sarah J Willis, et al.Clinical Oral Investigations|June 27, 2012
The randomized shortened dental arch study: tooth loss over five yearsM H Walter, W Hannak, M Kern, et al.The Journal of Pharmacology and Experimental Therapeutics|September 29, 2006
BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacologyX Ligneau, D Perrin, L Landais, et al.Pageof 61